Company intelligence / Profile preview

Atreus Pharmaceuticals

Ottawa, Ontario, Canadaatreus.de ↗

Ownership: Private
Development stage: Phase 2

Overview

Atreus Pharmaceuticals developed a SPECT radiopharmaceutical agent, technetium‑99m rhAnnexin V‑128, to detect early cell stress and apoptosis in vivo. The company initiated a Phase I/IIa clinical trial for this agent targeting rheumatoid arthritis and ankylosing spondylitis before being fully acquired by AAA in January 2015.

Therapeutic areas: CardiovascularRheumatologyImmunology
Modalities: Radiopharmaceuticals (SPECT imaging agents)Molecular imaging agents based on recombinant proteins
Industry: Biotech

Drug pipeline

1 asset

annexin V-128

Phase 2

Indications: Rheumatoid arthritis, Ankylosing spondylitis, Lymphoma, Lung cancer

Partnerships

Exclusive worldwide license with AAA for development of Annexin V‑128–based products prior to full acquisition.

Beyond the preview

Go deeper on Atreus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atreus Pharmaceuticals.

Explore the full profile